Alto Neuroscience logo

Alto NeuroscienceNYSE: ANRO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 February 2024

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$99.75 M
-82%vs. 3y high
43%vs. sector
-vs. 3y high
-vs. sector
-78%vs. 3y high
30%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 2 min ago
$3.70-$0.29(-7.27%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ANRO Latest News

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
businesswire.com04 November 2024 Sentiment: -

NEW YORK--(BUSINESS WIRE)-- #AltoNeuroscience--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. (“Alto Neuroscience” or “the Company”) (NYSE: ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO. Investigation Details On October 22, 2024, Alto Neuroscience announced that “the Phase 2b study o.

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
prnewswire.com03 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 3, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
accesswire.com03 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Investors to Reach Out
accesswire.com03 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Encouraged To Contact The Schall Law Firm
accesswire.com02 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Alto Neuroscience, Inc. (ANRO) Regarding Possible Securities Fraud Violations
accesswire.com30 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.

Alto Neuroscience, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ANRO
accesswire.com28 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
businesswire.com27 October 2024 Sentiment: NEGATIVE

NEW YORK--(BUSINESS WIRE)-- #AltoNeuroscience--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. (“Alto Neuroscience” or “the Company”) (NYSE: ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO. Investigation Details On October 22, 2024, Alto Neuroscience announced that “the Phase 2b study o.

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
accesswire.com27 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out
accesswire.com27 October 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.

  • 1(current)

What type of business is Alto Neuroscience?

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

What sector is Alto Neuroscience in?

Alto Neuroscience is in the Healthcare sector

What industry is Alto Neuroscience in?

Alto Neuroscience is in the Biotechnology industry

What country is Alto Neuroscience from?

Alto Neuroscience is headquartered in United States

When did Alto Neuroscience go public?

Alto Neuroscience initial public offering (IPO) was on 02 February 2024

What is Alto Neuroscience website?

https://www.altoneuroscience.com

Is Alto Neuroscience in the S&P 500?

No, Alto Neuroscience is not included in the S&P 500 index

Is Alto Neuroscience in the NASDAQ 100?

No, Alto Neuroscience is not included in the NASDAQ 100 index

Is Alto Neuroscience in the Dow Jones?

No, Alto Neuroscience is not included in the Dow Jones index

When was Alto Neuroscience the previous earnings report?

No data

When does Alto Neuroscience earnings report?

The next expected earnings date for Alto Neuroscience is 29 November 2024